Michael Celano - Jan 31, 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Financial Officer
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Stock symbol
LRMR
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 07:16 PM
Previous filing
Sep 19, 2022
Next filing
May 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LRMR Common Stock Award $0 +76K +239.4% $0.00 108K Jan 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +120K $0.00 120K Jan 31, 2023 Common Stock 120K $4.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.